Elsevier

Neurotherapeutics

Volume 4, Issue 1, January 2007, Pages 149-154
Neurotherapeutics

Part 2: Progress in current AED development: The drugs
Retigabine

https://doi.org/10.1016/j.nurt.2006.11.012Get rights and content
Under an Elsevier user license
open archive

Summary

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.

Key Words

Retigabine
potassium channels
partial-onset seizures
epilepsy

Cited by (0)